- Home
- RARE vs TENB Comparison
RARE vs TENB Comparison
Compare RARE & TENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- TENB
- Stock Information
- Founded
- RARE 2010
- TENB 2002
- Country
- RARE United States
- TENB United States
- Employees
- RARE N/A
- TENB N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- TENB Computer Software: Prepackaged Software
- Sector
- RARE Health Care
- TENB Technology
- Exchange
- RARE Nasdaq
- TENB Nasdaq
- Market Cap
- RARE 3.5B
- TENB 4.1B
- IPO Year
- RARE 2014
- TENB 2018
- Fundamental
- Price
- RARE $39.91
- TENB $33.64
- Analyst Decision
- RARE Strong Buy
- TENB Buy
- Analyst Count
- RARE 15
- TENB 19
- Target Price
- RARE $90.53
- TENB $40.33
- AVG Volume (30 Days)
- RARE 1.1M
- TENB 2.0M
- Earning Date
- RARE 07-31-2025
- TENB 07-30-2025
- Dividend Yield
- RARE N/A
- TENB N/A
- EPS Growth
- RARE N/A
- TENB N/A
- EPS
- RARE N/A
- TENB N/A
- Revenue
- RARE $590,689,000.00
- TENB $923,197,000.00
- Revenue This Year
- RARE $18.94
- TENB $10.61
- Revenue Next Year
- RARE $28.93
- TENB $7.88
- P/E Ratio
- RARE N/A
- TENB N/A
- Revenue Growth
- RARE 33.46
- TENB 11.79
- 52 Week Low
- RARE $29.59
- TENB $28.75
- 52 Week High
- RARE $60.37
- TENB $49.18
- Technical
- Relative Strength Index (RSI)
- RARE 65.02
- TENB 61.25
- Support Level
- RARE $35.51
- TENB $32.89
- Resistance Level
- RARE $38.19
- TENB $34.72
- Average True Range (ATR)
- RARE 1.58
- TENB 0.99
- MACD
- RARE 0.20
- TENB 0.13
- Stochastic Oscillator
- RARE 98.43
- TENB 80.18
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About TENB Tenable Holdings Inc.
Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.